RecruitingNot ApplicableNCT07124858

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

PRODIGE 108 - COHORTE 2320 - COFRUQ Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

Sponsor

Federation Francophone de Cancerologie Digestive

Enrollment

300 participants

Start Date

Mar 10, 2026

Study Type

INTERVENTIONAL

Conditions

Metastatic Colorectal Cancer (CRC)Antineoplastic Agents, Immunological VEGFR-TKI

Summary

The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fruquintinib for people with antineoplastic agents, immunological, metastatic colorectal cancer (crc), and other related conditions. The study is currently recruiting participants at 83 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFruquintinib

Fruquintinib will be administered according to the summary of product characteristics (SmPC) : 5 mg, 21 days of treatment followed by a 7-day break until progression, unacceptable toxicity, death, or patient refusal.

Locations(83)

Poitiers CHU

Poitiers, France, France

Centre Hospitalier

Albi, France

CHU

Amiens, France

Clinique de L Europe

Amiens, France

Centre Hospitalier

Annecy, France

Centre Hospitalier

Aurillac, France

Centre Hospitalier

Bayeux, France

Centre Hospitalier

Bayonne, France

Centre Hospitalier

Beauvais, France

CHU

Besançon, France

Centre Hospitalier Bethune Beuvry

Beuvry, France

Centre Pierre Curie

Beuvry, France

Clinique Tivoli

Bordeaux, France

Polynclinique Bordeaux Nord Aquitaine

Bordeaux, France

CHU

Brest, France

CHU

Caen, France

Centre Hospitalier

Calais, France

Infirmerie Protestante

Caluire-et-Cuire, France

Clinique Sainte Marie

Chalon-sur-Saône, France

ROC37

Chambray-lès-Tours, France

Centre Hospitalier

Chartres, France

Centre Hospitalier

Cholet, France

Clinique Sainte Come

Compiègne, France

Centre Hospitalier Sud Francilien

Corbeil-Essonnes, France

Clinique Branche - Clinique Flandres

Coudekerque-Branche, France

Centre Hospitalier Henri Mondor

Créteil, France

Centre Leonard de Vinci

Dechy, France

Chu Francois Mitterand

Dijon, France

Institut de Cancerologie de Bourgogne

Dijon, France

Hopital Prive Forcilles

Férolles-Attilly, France

Centre Hospitalier

Flers, France

CHI

Fréjus, France

Groupe Hospitalier Mutualiste

Grenoble, France

Polyclinique de Blois

La Chaussée-Saint-Victor, France

Clinique Sainte Clothilde

La Réunion, France

Centre Hospitalier de Vendee

La Roche-sur-Yon, France

Hopital Prive de L Estuaire

Le Havre, France

Centre Hospitalier

Le Puy-en-Velay, France

Centre Hospitalier

Lens, France

CHU

Lille, France

CHU

Limoges, France

Groupement Hospitalier Bretagne Sud

Lorient, France

Clinique Jean Mermoz

Lyon, France

Hopital Europeen

Marseille, France

Hopital Saint Joseph

Marseille, France

La Timone

Marseille, France

Clinique Gray

Maubeuge, France

Ch Du Mittan

Montbéliard, France

Institut de Cancerologie de Lorraine

Nancy, France

Hopital Prive Confluent

Nantes, France

Clinique Ambroise Pare Hartmann

Neuilly, France

Hopital Americain

Neuilly-sur-Seine, France

Centre Hospitalier

Niort, France

CH de la source

Orléans, France

BICHAT

Paris, France

COCHIN

Paris, France

Groupe Hospitalier Diaconesses Croix Saint Simon

Paris, France

Hopital Avicenne

Paris, France

Hopital Saint Louis

Paris, France

La Pitie Salepetriere

Paris, France

Saint Antoine

Paris, France

Centre Hospitalier

Pau, France

Hopital Instruction Des Armees

Percy, France

Centre Hospitalier

Perpignan, France

CHU

Pessac, France

Lyon Sud

Pierre-Bénite, France

Centre Cario

Plérin, France

CHU

Poitiers, France

CHU

Reims, France

CHU

Rennes, France

CHU

Rouen, France

Centre Hospitalier

Saint-Denis, France

Centre Hospitalier

Soissons, France

Centre Hospitalier

St-Malo, France

Clinique Sainte Anne

Strasbourg, France

Centre Hospitalier

Thonon-les-Bains, France

Chu Rangueil

Toulouse, France

CHU

Tours, France

Hopital Prive Drome Ardeche

Valence, France

CHU

Vandœuvre-lès-Nancy, France

Centre Hospitalier

Versailles, France

Hopital Nord Ouest

Villefranche-sur-Saône, France

Medipole Hopital Mutualiste

Villeurbanne, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07124858

Related Trials

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

NCT077242231 location

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

NCT075002981 location

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832140 locations

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT0691707917 locations

Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)

NCT075361131 location